For the year ending 2025-12-31, MAZE has $397,127K in assets. $42,161K in debts. $189,247K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 189,247 | |||
| Marketable securities, current | 152,670 | |||
| Prepaid expenses and other current assets | 7,800 | |||
| Total current assets | 349,717 | |||
| Total property and equipment, gross | 24,255 | |||
| Accumulated depreciation | 19,211 | |||
| Property and equipment, net | 5,044 | |||
| Restricted cash | 1,088 | |||
| Marketable securities, non-current | 18,114 | |||
| Operating lease right-of-use asset | 20,116 | |||
| Other assets | 3,048 | |||
| Total assets | 397,127 | |||
| Accounts payable | 1,794 | |||
| Accrued expenses and other current liabilities | 15,967 | |||
| Operating lease liabilities, current | 4,795 | |||
| Total current liabilities | 22,556 | |||
| Operating lease liabilities, net of current portion | 18,511 | |||
| Other liabilities, non-current | 1,094 | |||
| Total liabilities | 42,161 | |||
| Common stock, 0.001 par value 500,000,000 and 410,000,000 shares authorized as of december 31, 2025 and 2024, respectively 49,335,551 and 2,446,864 shares issued and outstanding as of december 31, 2025 and 2024, respectively 10,372 shares subject to repurchase as of december 31, 2025 and 2024 | 49 | |||
| Additional paid-in-capital | 844,354 | |||
| Accumulated other comprehensive income | 110 | |||
| Accumulated deficit | -489,547 | |||
| Total stockholders' equity (deficit) | 354,966 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 397,127 | |||
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)